An understanding of external validity becomes of utmost relevance among SGLT2-i CVOTs because most of the recent guidelines has strengthened the role of SGLT2i in the management of T2D patients [12]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.